IONIC is exploring the potential of Veyonda to increase the activity of Bristol Myers Squibb's PBS-listed immune checkpoint inhibitor OPDIVO (nivolumab) in different types of cancer.
Noxopharm provides an update on trial of its oncology drug candidate
December 4, 2022 Australian BiotechBioPharmaLatest Video
New Stories
-
Gilead announces eight recipients of inaugural Community Grants Program
March 28, 2024 - - Latest News -
Groups call for a new approach to reviewing and funding cancer medicines
March 28, 2024 - - Latest News -
Auditor General extends time to contribute to PBS performance audit
March 28, 2024 - - Latest News -
Reform bill redefines political donation and could exclude the industry from participating
March 27, 2024 - - Latest News -
NZ Government delivers funding boost for patients travelling to health treatment
March 27, 2024 - - Latest News -
Clarity Pharmaceuticals launches $121 million fully underwritten equity raising
March 26, 2024 - - Australian Biotech -
More states announce RSV programs as families call for national action
March 26, 2024 - - Latest News